Related Experiment Video
Updated: Aug 11, 2026
09:40
Analysis of the c-KIT Ligand Promoter Using Chromatin Immunoprecipitation
Published on: June 27, 2017
Stem cell factor and its receptor c-Kit as targets for inflammatory diseases
Laurent Reber1, Carla A Da Silva, Nelly Frossard
1EA 3771 Inflammation and Environment in Asthma, Université Louis Pasteur-Strasbourg-I, Faculté de Pharmacie, Illkirch, France. lreber@pharma.u-strasbg.fr
European Journal of Pharmacology
|February 18, 2006
Summary
Stem cell factor (SCF) activates pathways involved in airway inflammation. Inhibiting the SCF/c-Kit pathway reduces mast cells, eosinophils, and airway hyperresponsiveness, suggesting it as a therapeutic target.
Area of Science:
- Immunology
- Cell Biology
- Respiratory Medicine
Background:
- Stem cell factor (SCF) is the ligand for the c-Kit receptor.
- SCF is expressed by airway structural and inflammatory cells.
- SCF binding activates multiple intracellular signaling pathways.
Purpose of the Study:
- To investigate the role of SCF/c-Kit signaling in airway inflammation.
- To evaluate the therapeutic potential of inhibiting the SCF/c-Kit pathway.
Main Methods:
- In vitro and in vivo studies using human and mouse models.
- Analysis of cellular responses, cytokine production, and airway hyperresponsiveness.
- Assessment of the effects of SCF/c-Kit pathway inhibition.
Main Results:
- SCF promotes mast cell generation, survival, and degranulation, releasing histamine and inflammatory mediators.
- SCF enhances eosinophil adhesion and activation.
- SCF upregulation is observed in inflammatory conditions.
- Inhibition of SCF/c-Kit significantly reduces histamine, mast cells, eosinophils, IL-4, and airway hyperresponsiveness.
Conclusions:
- The SCF/c-Kit pathway plays a critical role in mast cell and eosinophil-mediated airway inflammation.
- Targeting the SCF/c-Kit pathway offers a potential therapeutic strategy for inflammatory airway diseases.
Related Concept Videos
01:01Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...